68Ga-labeled NY108 PET Imaging in Patients
This is a single arm study to evaluate the safety and biodistribution of 68Ga-labeled NY108 (68Ga-NY108) PET Imaging in patients.
Prostatic Cancer
DRUG: 68Ga-labeled NY108
Evaluation of tissue distribution of 68Ga-Anti-PSMA mAbs(NY108), Biodistribution of 68Ga-Anti-PSMA mAbs(NY108) evaluated by radioactive uptake values (standardized uptake values, SUVs) in various organs during repeated 68Ga-PET scans will be reported., 1 year
Incidence of Treatment-Emergent Adverse Events, Safety will be assessed by evaluation of incidence of adverse events., 1 year
This is a single arm study to evaluate the safety and biodistribution of 68Ga-labeled NY108 (68Ga-NY108) PET Imaging in patients.